{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:05:03Z","timestamp":1749269103754,"version":"3.41.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,6]]},"DOI":"10.7759\/cureus.85461","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T13:11:40Z","timestamp":1749215500000},"source":"Crossref","is-referenced-by-count":0,"title":["Management of Pseudomonas Urinary Tract Infections (UTIs) in the Context of Extensive Antibiotic Anaphylaxis: A Case-Based Perspective"],"prefix":"10.7759","author":[{"given":"Ryan N","family":"Gibson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben Hurr","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287219832172","article-title":"An introduction to the epidemiology and burden of urinary tract infections","volume":"11","author":"Medina M","year":"2019","unstructured":"Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019, 11:1756287219832172. 10.1177\/1756287219832172","journal-title":"Ther Adv Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2009.08.003","article-title":"Urinary tract infections caused by Pseudomonas aeruginosa: a minireview","volume":"2","author":"Mittal R","year":"2009","unstructured":"Mittal R, Aggarwal S, Sharma S, Chhibber S, Harjai K. Urinary tract infections caused by Pseudomonas aeruginosa: a minireview. J Infect Public Health. 2009, 2:101-11. 10.1016\/j.jiph.2009.08.003","journal-title":"J Infect Public Health"},{"key":"ref3","unstructured":"Pseudomonas aeruginosa. (2016). Accessed. April 20, 2025:  https:\/\/www.microbiologyinpictures.com\/pseudomonas-aeruginosa.html."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv043","article-title":"Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years","volume":"70","author":"Ironmonger D","year":"2015","unstructured":"Ironmonger D, Edeghere O, Bains A, Loy R, Woodford N, Hawkey PM. Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years. J Antimicrob Chemother. 2015, 70:1744-50. 10.1093\/jac\/dkv043","journal-title":"J Antimicrob Chemother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang Z","year":"2019","unstructured":"Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019, 37:177-92. 10.1016\/j.biotechadv.2018.11.013","journal-title":"Biotechnol Adv"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles AL","year":"2015","unstructured":"Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015, 13:269-84. 10.1038\/nrmicro3432","journal-title":"Nat Rev Microbiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S185753","article-title":"Risk factors and prognosis of complicated urinary tract infections caused by Pseudomonas aeruginosa in hospitalized patients: a retrospective multicenter cohort study","volume":"11","author":"Gomila A","year":"2018","unstructured":"Gomila A, Carratal\u00e0 J, Eliakim-Raz N, et al.. Risk factors and prognosis of complicated urinary tract infections caused by Pseudomonas aeruginosa in hospitalized patients: a retrospective multicenter cohort study. Infect Drug Resist. 2018, 11:2571-81. 10.2147\/IDR.S185753","journal-title":"Infect Drug Resist"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1374466","article-title":"Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies","volume":"15","author":"Elfadadny A","year":"2024","unstructured":"Elfadadny A, Ragab RF, AlHarbi M, et al.. Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies. Front Microbiol. 2024, 15:1374466. 10.3389\/fmicb.2024.1374466","journal-title":"Front Microbiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90435-8","article-title":"Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa","volume":"78","author":"Scully BE","year":"1985","unstructured":"Scully BE, Neu HC. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. Am J Med. 1985, 78:251-61. 10.1016\/0002-9343(85)90435-8","journal-title":"Am J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4557-4801-3.00022-9","article-title":"Chapter 22-other \u03b2-lactam antibiotics","author":"Chambers","year":"2015","unstructured":"Chambers, H. and Doi, Y.. Chapter 22-other \u03b2-lactam antibiotics. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition). Bennett JE, Dolin R, Blaser MJ (ed): Saunders, Philadelphia, PA; 2015. 1:293-7. 10.1016\/B978-1-4557-4801-3.00022-9"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-820472-6.00212-7","article-title":"7.02 - Beta lactam","author":"Iyer RN","year":"2022","unstructured":"Iyer RN. 7.02 - Beta lactam. Compr Pharmacol. 2022, 3-63. 10.1016\/B978-0-12-820472-6.00212-7","journal-title":"Compr Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/348187-management-of-pseudomonas-urinary-tract-infections-utis-in-the-context-of-extensive-antibiotic-anaphylaxis-a-case-based-perspective","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T13:11:41Z","timestamp":1749215501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/348187-management-of-pseudomonas-urinary-tract-infections-utis-in-the-context-of-extensive-antibiotic-anaphylaxis-a-case-based-perspective"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.85461","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,6]]}}}